Sana Biotechnology IncNASDAQ:SANA
- LAST PRICE7.5000
- TODAY'S CHANGE (%)-0.1100 (-1.4455%)
- Bid / Lots7.5000/ 10
- Ask / Lots7.7500/ 11
- Open / Previous Close7.6600 / 7.6100
- Day Range
- 52 Week Range
- Volume2,569,190
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SANA |
|---|---|---|
| 09:32 ET | 6925 | 7.77 |
| 09:34 ET | 300 | 7.71 |
| 09:36 ET | 2892 | 7.77 |
| 09:38 ET | 325 | 7.81 |
| 09:39 ET | 212 | 7.84 |
| 09:41 ET | 8847 | 7.84 |
| 09:43 ET | 1583 | 7.82 |
| 09:45 ET | 1100 | 7.775 |
| 09:48 ET | 37300 | 7.78 |
| 09:50 ET | 12689 | 7.82 |
| 09:52 ET | 1675 | 7.86 |
| 09:54 ET | 2708 | 7.84 |
| 09:56 ET | 2674 | 7.83 |
| 09:57 ET | 2560 | 7.82 |
| 09:59 ET | 1206 | 7.82 |
| 10:01 ET | 1680 | 7.79 |
| 10:03 ET | 3724 | 7.795 |
| 10:06 ET | 500 | 7.81 |
| 10:08 ET | 4637 | 7.815 |
| 10:10 ET | 4518 | 7.82 |
| 10:12 ET | 1742 | 7.805 |
| 10:14 ET | 2366 | 7.785 |
| 10:15 ET | 1750 | 7.79 |
| 10:17 ET | 1950 | 7.79 |
| 10:19 ET | 500 | 7.79 |
| 10:21 ET | 4830 | 7.86 |
| 10:24 ET | 1631 | 7.87 |
| 10:26 ET | 1182 | 7.775 |
| 10:28 ET | 700 | 7.77 |
| 10:30 ET | 890 | 7.78 |
| 10:32 ET | 600 | 7.77 |
| 10:33 ET | 1804 | 7.78 |
| 10:35 ET | 778 | 7.78 |
| 10:37 ET | 300 | 7.765 |
| 10:39 ET | 4487 | 7.785 |
| 10:42 ET | 2592 | 7.78 |
| 10:44 ET | 855 | 7.77 |
| 10:46 ET | 5841 | 7.76 |
| 10:48 ET | 2677 | 7.73 |
| 10:50 ET | 1454 | 7.73 |
| 10:51 ET | 1218 | 7.73 |
| 10:53 ET | 1513 | 7.735 |
| 10:55 ET | 894 | 7.745 |
| 10:57 ET | 2096 | 7.75 |
| 11:00 ET | 1200 | 7.74 |
| 11:02 ET | 935 | 7.74 |
| 11:04 ET | 4375 | 7.68 |
| 11:06 ET | 3523 | 7.685 |
| 11:08 ET | 2716 | 7.6922 |
| 11:09 ET | 1820 | 7.71 |
| 11:11 ET | 912 | 7.71 |
| 11:13 ET | 3842 | 7.695 |
| 11:15 ET | 1340 | 7.68 |
| 11:18 ET | 346 | 7.69 |
| 11:20 ET | 637 | 7.69 |
| 11:22 ET | 4217 | 7.675 |
| 11:24 ET | 2400 | 7.67 |
| 11:26 ET | 3572 | 7.67 |
| 11:27 ET | 403 | 7.665 |
| 11:29 ET | 920 | 7.665 |
| 11:31 ET | 700 | 7.665 |
| 11:33 ET | 1928 | 7.65 |
| 11:36 ET | 1500 | 7.645 |
| 11:38 ET | 3468 | 7.65 |
| 11:40 ET | 200 | 7.6499 |
| 11:42 ET | 500 | 7.645 |
| 11:44 ET | 1000 | 7.66 |
| 11:45 ET | 2670 | 7.655 |
| 11:47 ET | 1600 | 7.67 |
| 11:49 ET | 800 | 7.68 |
| 11:51 ET | 100 | 7.675 |
| 11:54 ET | 1314 | 7.665 |
| 11:56 ET | 3636 | 7.69 |
| 11:58 ET | 6228 | 7.695 |
| 12:00 ET | 700 | 7.685 |
| 12:02 ET | 1200 | 7.675 |
| 12:03 ET | 1606 | 7.66 |
| 12:05 ET | 300 | 7.66 |
| 12:07 ET | 1700 | 7.65 |
| 12:09 ET | 2200 | 7.655 |
| 12:12 ET | 2200 | 7.655 |
| 12:14 ET | 3744 | 7.635 |
| 12:16 ET | 1753 | 7.66 |
| 12:18 ET | 2600 | 7.645 |
| 12:20 ET | 410 | 7.65 |
| 12:21 ET | 1677 | 7.635 |
| 12:23 ET | 3396 | 7.635 |
| 12:25 ET | 1335 | 7.64 |
| 12:27 ET | 478 | 7.64 |
| 12:30 ET | 400 | 7.64 |
| 12:32 ET | 300 | 7.635 |
| 12:34 ET | 470 | 7.635 |
| 12:36 ET | 1300 | 7.6499 |
| 12:38 ET | 1565 | 7.635 |
| 12:39 ET | 1900 | 7.63 |
| 12:41 ET | 3868 | 7.64 |
| 12:43 ET | 600 | 7.635 |
| 12:45 ET | 300 | 7.65 |
| 12:48 ET | 923 | 7.65 |
| 12:50 ET | 400 | 7.65 |
| 12:52 ET | 2409 | 7.65 |
| 12:54 ET | 3111 | 7.635 |
| 12:56 ET | 888 | 7.64 |
| 12:57 ET | 659 | 7.64 |
| 12:59 ET | 406 | 7.65 |
| 01:01 ET | 1300 | 7.65 |
| 01:03 ET | 6178 | 7.645 |
| 01:06 ET | 5635 | 7.615 |
| 01:08 ET | 8161 | 7.61 |
| 01:10 ET | 2205 | 7.61 |
| 01:12 ET | 1000 | 7.62 |
| 01:14 ET | 200 | 7.625 |
| 01:15 ET | 200 | 7.63 |
| 01:17 ET | 2932 | 7.615 |
| 01:21 ET | 400 | 7.62 |
| 01:24 ET | 2138 | 7.63 |
| 01:26 ET | 100 | 7.64 |
| 01:28 ET | 5945 | 7.635 |
| 01:30 ET | 689 | 7.635 |
| 01:32 ET | 2345 | 7.625 |
| 01:33 ET | 200 | 7.625 |
| 01:35 ET | 400 | 7.625 |
| 01:37 ET | 8636 | 7.59 |
| 01:39 ET | 1310 | 7.59 |
| 01:42 ET | 1272 | 7.57 |
| 01:44 ET | 1400 | 7.57 |
| 01:46 ET | 600 | 7.575 |
| 01:48 ET | 678 | 7.57 |
| 01:50 ET | 1200 | 7.58 |
| 01:51 ET | 600 | 7.59 |
| 01:53 ET | 2128 | 7.57 |
| 01:55 ET | 1798 | 7.565 |
| 01:57 ET | 1089 | 7.555 |
| 02:00 ET | 1125 | 7.555 |
| 02:02 ET | 2989 | 7.57 |
| 02:04 ET | 1146 | 7.565 |
| 02:06 ET | 21900 | 7.56 |
| 02:08 ET | 860 | 7.555 |
| 02:09 ET | 3868 | 7.565 |
| 02:11 ET | 400 | 7.565 |
| 02:13 ET | 1751 | 7.56 |
| 02:15 ET | 2987 | 7.575 |
| 02:18 ET | 2013 | 7.58 |
| 02:20 ET | 900 | 7.585 |
| 02:22 ET | 1864 | 7.585 |
| 02:24 ET | 2007 | 7.585 |
| 02:26 ET | 700 | 7.59 |
| 02:27 ET | 3224 | 7.565 |
| 02:29 ET | 6026 | 7.575 |
| 02:31 ET | 3111 | 7.57 |
| 02:36 ET | 700 | 7.575 |
| 02:38 ET | 3466 | 7.565 |
| 02:40 ET | 2895 | 7.55 |
| 02:42 ET | 4726 | 7.56 |
| 02:44 ET | 1099 | 7.56 |
| 02:45 ET | 3257 | 7.565 |
| 02:47 ET | 2093 | 7.555 |
| 02:49 ET | 1721 | 7.545 |
| 02:51 ET | 2615 | 7.5233 |
| 02:54 ET | 24206 | 7.535 |
| 02:56 ET | 6189 | 7.56 |
| 02:58 ET | 1867 | 7.565 |
| 03:00 ET | 800 | 7.565 |
| 03:02 ET | 2713 | 7.55 |
| 03:03 ET | 4752 | 7.535 |
| 03:05 ET | 1833 | 7.53 |
| 03:07 ET | 950 | 7.535 |
| 03:09 ET | 3602 | 7.54 |
| 03:12 ET | 800 | 7.545 |
| 03:14 ET | 6411 | 7.555 |
| 03:16 ET | 2020 | 7.56 |
| 03:18 ET | 840 | 7.555 |
| 03:20 ET | 6104 | 7.525 |
| 03:21 ET | 3842 | 7.54 |
| 03:23 ET | 4298 | 7.555 |
| 03:25 ET | 1822 | 7.555 |
| 03:27 ET | 1962 | 7.58 |
| 03:30 ET | 9246 | 7.545 |
| 03:32 ET | 2549 | 7.54 |
| 03:34 ET | 4100 | 7.54 |
| 03:36 ET | 8020 | 7.54 |
| 03:38 ET | 2012 | 7.545 |
| 03:39 ET | 2475 | 7.55 |
| 03:41 ET | 36896 | 7.545 |
| 03:43 ET | 7734 | 7.54 |
| 03:45 ET | 5712 | 7.54 |
| 03:48 ET | 5652 | 7.53 |
| 03:50 ET | 19776 | 7.5 |
| 03:52 ET | 41684 | 7.545 |
| 03:54 ET | 17763 | 7.535 |
| 03:56 ET | 69537 | 7.51 |
| 03:57 ET | 59207 | 7.495 |
| 03:59 ET | 40280 | 7.5 |
May 21, 2024
Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington's Disease and Other Glial-based Neurodegenerative Conditions, from 9:00AM ET on Tuesday May 21, 2024 by Dow Jones
9:00AM ET on Tuesday May 21, 2024 by Dow Jones
May 9, 2024
DJ Sana Biotechnology Price Target Maintained With a $12.00/Share by HC Wainwright & Co., from 3:32PM ET on Thursday May 09, 2024 by Dow Jones
3:32PM ET on Thursday May 09, 2024 by Dow Jones
May 8, 2024
Press Release: Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates, from 4:05PM ET on Wednesday May 08, 2024 by Dow Jones
4:05PM ET on Wednesday May 08, 2024 by Dow JonesSana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates, from 4:05PM ET on Wednesday May 08, 2024 by Dow Jones
4:05PM ET on Wednesday May 08, 2024 by Dow Jones
May 6, 2024
Sana Biotechnology to Present at May and June 2024 Investor Conferences, from 4:05PM ET on Monday May 06, 2024 by Dow Jones
4:05PM ET on Monday May 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sana Biotechnology Inc | 1.7B | -4.9x | --- |
Syndax Pharmaceuticals Inc | 1.6B | -6.0x | --- |
Keros Therapeutics Inc | 1.7B | -9.1x | --- |
Edgewise Therapeutics Inc | 1.6B | -11.2x | --- |
Structure Therapeutics Inc | 1.6B | -14.7x | --- |
Neumora Therapeutics Inc | 1.6B | -4.1x | --- |
Company Information
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. It is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. It is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. It is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.
Contact Information
- Headquarters
- 188 East Blaine Street, Suite 400SEATTLE, WA, United States 98102
- Phone
- 206-701-7914
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Hans Bishop
- President, Chief Executive Officer
- Steven Harr
- Vice Chairman of the Board and Head of SanaX
- Richard Mulligan
- Chief Financial Officer, Executive Vice President
- Nathan Hardy
- Executive Vice President, General Counsel, Company Secretary
- Bernard Cassidy
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.7B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 221.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.53 |
Book Value | $1.45 |
P/E Ratio | -4.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
